Skip to the page

Data / Drug companies / Merck Sharp & Dohme LLC

Merck Sharp & Dohme LLC: 11 products in the FDA NDC directory, labeler code 0085

Merck Sharp & Dohme LLC (labeler code 0085) lists 11 products in the FDA National Drug Code Directory, covering 2 finished drugs by generic name. By type: 11 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on June 8, 2021.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0085
Products in commercial distribution
11
Packages
16
Finished drugs by generic name
2
Prescription products
11
Over the counter products
0
Flagged as original packager
11 of 11 products that carry the flag
Started marketing in the last 12 months
0
Earliest marketing start
August 11, 1999
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
New drug applications (NDA)11100%

Products by type

TypeProductsShare
Prescription drugs11100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

DrugProductsCompanies listing it
Temozolomide712
Posaconazole429

Dosage forms

Dosage formProductsShare
Capsule654.5%
Suspension19.1%
Injection, powder, lyophilized, for solution19.1%
Tablet, coated19.1%
Solution19.1%
Powder, for suspension19.1%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Noxafil0085-2224Powder, for suspensionNew drug applications (NDA)June 8, 2021
Noxafil0085-4331SolutionNew drug applications (NDA)March 13, 2014
Noxafil0085-4324Tablet, coatedNew drug applications (NDA)November 25, 2013
Temodar0085-1381Injection, powder, lyophilized, for solutionNew drug applications (NDA)February 27, 2009
Noxafil0085-1328SuspensionNew drug applications (NDA)September 15, 2006
Temodar0085-3004CapsuleNew drug applications (NDA)August 11, 1999
Temodar0085-1519CapsuleNew drug applications (NDA)August 11, 1999
Temodar0085-1430CapsuleNew drug applications (NDA)August 11, 1999
Temodar0085-1425CapsuleNew drug applications (NDA)August 11, 1999
Temodar0085-1417CapsuleNew drug applications (NDA)August 11, 1999
Temodar0085-1366CapsuleNew drug applications (NDA)August 11, 1999

Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.